Welcome to our dedicated page for aTyr Pharma SEC filings (Ticker: LIFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating cash-runway figures, pipeline updates, or patent disclosures in aTyr Pharma’s SEC documents can feel like decoding an advanced biology textbook. Each 10-K details physiocrine biology breakthroughs, while every 8-K announces pivotal clinical data that may move the share price overnight. If you have ever searched for aTyr Pharma SEC filings explained simply, you know the challenge.
Stock Titan eliminates the guesswork. Our AI parses every aTyr Pharma annual report 10-K simplified, extracts R&D spend, and flags risks in seconds. Need the latest aTyr Pharma quarterly earnings report 10-Q filing? We publish it the moment it hits EDGAR and provide side-by-side trend analysis. Real-time alerts surface aTyr Pharma Form 4 insider transactions real-time so you can monitor aTyr Pharma executive stock transactions Form 4 before the market reacts. From aTyr Pharma 8-K material events explained to aTyr Pharma proxy statement executive compensation, every filing is paired with AI-powered summaries that translate clinical jargon into clear insights.
Use these insights to:
- Track trial milestones without combing through hundreds of pages
- Compare quarter-over-quarter R&D trends via our aTyr Pharma earnings report filing analysis
- Spot sentiment shifts with aTyr Pharma insider trading Form 4 transactions
On 06/30/2025, The Vanguard Group filed Amendment No. 10 to Schedule 13G reporting its ownership of Chemours Company (CC) common stock.
- Shares beneficially owned: 17,663,980
- Ownership percentage: 11.8 % of outstanding shares
- Voting power: 0 sole; 181,238 shared
- Dispositive power: 17,324,381 sole; 339,599 shared
Vanguard qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E). The firm states the position is held in the ordinary course of business and not to influence control. Clients of Vanguard retain rights to dividends and sale proceeds.
Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially enhancing liquidity and investor confidence, although its near-zero sole voting power limits direct governance influence.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What is the core focus of aTyr Pharma, Inc.?
What therapeutic area does resolaris™ target?
How does aTyr Pharma protect its intellectual property?
What role does physiocrine biology play in aTyr Pharma's research?
Which clinical conditions are being addressed in the company’s trials?
How does aTyr Pharma generate revenue from its business model?
How is aTyr Pharma positioned within the competitive biotechnology landscape?
What distinguishes aTyr Pharma's approach to drug development?
